These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28370222)

  • 21. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
    Poordad F; Bennett M; Sepe TE; Cohen E; Reindollar RW; Everson G; Phillips RW; Siddique A; Sullivan JG; Pilot-Matias T; Abunimeh M; Cohen DE; Younes Z
    J Med Virol; 2019 Jul; 91(7):1307-1312. PubMed ID: 30840774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.
    Poordad F; Castro RE; Asatryan A; Aguilar H; Cacoub P; Dieterich D; Marinho RT; Carvalho A; Siddique A; Hu YB; Charafeddine M; Bondin M; Khan N; Cohen DE; Felizarta F
    J Viral Hepat; 2020 May; 27(5):497-504. PubMed ID: 31954087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
    Welzel TM; Hinrichsen H; Sarrazin C; Buggisch P; Baumgarten A; Christensen S; Berg T; Mauss S; Teuber G; Stein K; Deterding K; van Bömmel F; Heyne R; John C; Zimmermann T; Lutz T; Schott E; Hettinger J; Kleine H; König B; Hüppe D; Wedemeyer H
    J Viral Hepat; 2017 Oct; 24(10):840-849. PubMed ID: 28342229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients.
    Fofiu C; Boeriu A; Coman F; Fofiu A; Panic N; Bulajic M; Dobru D
    Ann Hepatol; 2019; 18(1):137-143. PubMed ID: 31113582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
    Rosenthal P; Narkewicz MR; Yao BB; Jolley CD; Lobritto SJ; Wen J; Molleston JP; Hsu EK; Jonas MM; Zha J; Liu L; Leung DH
    Adv Ther; 2020 Jul; 37(7):3299-3310. PubMed ID: 32451952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir combined with ribavirin in Asian adult patients with chronic HCV genotype 1b infection and compensated cirrhosis].
    Wei L; Wang GQ; Sarah J; Cheng Q; Xie MR; Wang M; Xu ZP; Duan JL; Hou MX; Zhang YX; Zhang G; Tang W; Zhao SM; Lin ZS; Jia JJ; Niu ZL; Gao H; Yuan MH; Lin XM; Zhou JD; Luo Y; Linda F; Niloufar M; Wang Y; Jia J
    Zhonghua Gan Zang Bing Za Zhi; 2018 May; 26(5):353-358. PubMed ID: 29996203
    [No Abstract]   [Full Text] [Related]  

  • 27. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.
    Wedemeyer H; Craxí A; Zuckerman E; Dieterich D; Flisiak R; Roberts SK; Pangerl A; Zhang Z; Martinez M; Bao Y; Calleja JL
    J Viral Hepat; 2017 Nov; 24(11):936-943. PubMed ID: 28480525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
    Crespo J; Calleja JL; Fernández I; Sacristan B; Ruiz-Antorán B; Ampuero J; Hernández-Conde M; García-Samaniego J; Gea F; Buti M; Cabezas J; Lens S; Morillas RM; Salcines JR; Pascasio JM; Turnes J; Sáez-Royuela F; Arenas J; Rincón D; Prieto M; Jorquera F; Sanchez Ruano JJ; Navascués CA; Molina E; Moya AG; Moreno-Planas JM;
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):945-949.e1. PubMed ID: 28238958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
    Preda CM; Popescu CP; Baicus C; Voiosu TA; Manuc M; Pop CS; Gheorghe L; Sporea I; Trifan A; Tantau M; Tantau A; Ceausu E; Proca D; Constantinescu I; Ruta SM; Diculescu MM; Oproiu A
    Liver Int; 2018 Apr; 38(4):602-610. PubMed ID: 28816020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
    Londoño MC; Riveiro-Barciela M; Ahumada A; Muñoz-Gómez R; Roget M; Devesa-Medina MJ; Serra MÁ; Navascués CA; Baliellas C; Aldamiz-Echevarría T; Gutiérrez ML; Polo-Lorduy B; Carmona I; Benlloch S; Bonet L; García-Samaniego J; Jiménez-Pérez M; Morán-Sánchez S; Castro Á; Delgado M; Gea-Rodríguez F; Martín-Granizo I; Montes ML; Morano L; Castaño MA; de Los Santos I; Laguno M; Losa JE; Montero-Alonso M; Rivero A; de Álvaro C; Manzanares A; Mallolas J; Barril G; González-Parra E; García-Buey L
    PLoS One; 2019; 14(9):e0221567. PubMed ID: 31550267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C: efficacy and safety in real life.
    Flisiak R; Pogorzelska J; Flisiak-Jackiewicz M
    Liver Int; 2017 Jan; 37 Suppl 1():26-32. PubMed ID: 28052633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and safety of paritaprevir/ritonavir/ombitasvir combined with dasabuvir in non-cirrhotic Asian adult patients with newly diagnosed and treated chronic HCV genotype 1b infection: a randomized, double-blind, placebo-controlled study - China data].
    Wei L; Cheng J; Luo J; Li ZP; Duan JL; Hou JD; Jia MX; Zhang Y; Huang Q; Xie GJ; Wang DL; Yang W; Zhao CY; Zhao G; Tang SM; Lin GZ; Gong JJ; Niu ZL; Gao JF; Sarah KB; Linda F; Niloufar M; Wang Y; Wang J
    Zhonghua Gan Zang Bing Za Zhi; 2018 May; 26(5):359-364. PubMed ID: 29996204
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
    Rockstroh JK; Orkin C; Viani RM; Wyles D; Luetkemeyer AF; Lazzarin A; Soto-Malave R; Nelson MR; Bhagani SR; Klinker HHF; Rizzardini G; Girard PM; Tural C; Shulman NS; Mobashery N; Hu YB; Fredrick LM; Pilot-Matias T; Trinh R; Gane E
    Open Forum Infect Dis; 2017; 4(3):ofx154. PubMed ID: 28948180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice.
    González-Colominas E; Londoño MC; Morillas RM; Torras X; Mojal S; Lens S; López D; Gallego A; Mariño Z; Ardèvol M; Pagès N; Solà R; Carrión JA
    J Gastroenterol Hepatol; 2018 May; 33(5):1100-1107. PubMed ID: 28994141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Burden of disease in patients with chronic hepatitis C in the Austrian REAL study.
    Gschwantler M; Bamberger T; Graziadei I; Maieron A; Katalinic N; Stauber R
    Wien Klin Wochenschr; 2019 Jan; 131(1-2):8-16. PubMed ID: 30430232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1.
    Miyasaka A; Yoshida Y; Yoshida T; Murakami A; Abe K; Ohuchi K; Kawakami T; Watanabe D; Hoshino T; Sawara K; Takikawa Y
    Intern Med; 2018 Oct; 57(19):2807-2812. PubMed ID: 29780135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan.
    Virabhak S; Yasui K; Yamazaki K; Johnson S; Mitchell D; Yuen C; Samp JC; Igarashi A
    J Med Econ; 2016 Dec; 19(12):1144-1156. PubMed ID: 27348464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
    Kumada H; Chayama K; Rodrigues L; Suzuki F; Ikeda K; Toyoda H; Sato K; Karino Y; Matsuzaki Y; Kioka K; Setze C; Pilot-Matias T; Patwardhan M; Vilchez RA; Burroughs M; Redman R
    Hepatology; 2015 Oct; 62(4):1037-46. PubMed ID: 26147154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
    Darvishian M; Wong S; Binka M; Yu A; Ramji A; Yoshida EM; Wong J; Rossi C; Butt ZA; Bartlett S; Pearce ME; Samji H; Cook D; Alvarez M; Chong M; Tyndall M; Krajden M; Janjua NZ
    J Viral Hepat; 2020 Mar; 27(3):243-260. PubMed ID: 31664755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir for the treatment of chronic hepatitis C 1b genotype infection in China].
    Jie YS; Yuan J; Zhang XH; Guan YJ; Zhao ZX; Chong YT; Tao L; Li JP; Lin CS
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):123-127. PubMed ID: 30818917
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.